News

October 19, 2024

Vactech Appoints Dr. Tero Välimaa as New Chief Executive Officer.


Experienced Leader Brings Over 25 Years of Pharmaceutical and Medical Device Expertise to Vactech
February 19, 2024

The results of the PRV-101 vaccine Phase I trial published in Diabetologia.


Diabetologia is the official journal of the European Association for the Study of Diabetes. It is dedicated to the study of diabetes, offering high visibility through society...
March 28, 2022

Vactech announces positive final results from First-In-Human study of Coxsackievirus B Vaccine Candidate PRV-101.


PRV-101 continued to be well tolerated and elicited durable high titers of virus-neutralizing antibodies in a dose-dependent fashion in...
November 1, 2021

Vactech announces positive interim results from First-in-Human Study of Coxsackievirus B Vaccine Candidate PRV-101 against Type 1 Diabetes.


PRV-101 was well tolerated and elicited high titers of virus-neutralizing antibodies in a dose-dependent...
January 27, 2021

Vactech announces that the First-in-Human Study of Coxsackievirus B Vaccine Candidate PRV-101 has been initiated.


Potential to be the first vaccine for the prevention of coxsackievirus B, a presumed infectious trigger in the development of Type 1...
May 18, 2020

Vactech and Provention Bio announce publication of proof-of-concept data for a preclinical prototype of coxsackievirus B vaccine.


A preclinical prototype of Provention's polyvalent coxsackievirus B vaccine, PRV-101, is well-tolerated, immunogenic and...
March 4, 2020

Vactech announces issuance of US patent for Multi-CBV vaccine for preventing or treating Type 1 Diabetes.


The present invention relates to anti-viral compositions e. g. vaccines and methods useful in preventing or treating Type 1 Diabetes (T1D)...
April 9, 2018

A Coxsackievirus B vaccine protects against virus-induced diabetes in an experimental mouse model of Type 1 Diabetes.


Coxsackievirus B vaccine protects against virus-induced diabetes in an experimental mouse model of Type 1 Diabetes and the research...
July 18, 2017

Vactech announces a US-based strategic partnership and clinical development program focused on intercepting and preventing the onset of Type 1 Diabetes.


Lead asset out-licensed to Provention Bio, Inc. for the development of a vaccine preventing Type...
January 13, 2017

Vactech announces issuance of EPO patent for Multi-CBV vaccine for preventing or treating Type 1 Diabetes.


The present invention relates to anti-viral compositions e. g. vaccines and methods useful in preventing or treating Type 1 Diabetes (T1D). More...
October 26, 2016

Vactech announces issuance of EPO patent for Diagnostic Assay for Type 1 Diabetes.


The present invention relates to a diagnostic assay for Type 1 Diabetes (T1D), and especially to an assay for predicting the risk of contracting the disease. It also...
December 9, 2015

Vactech announces issuance of EPO patent for Prevention of Allergic Sensitization.


This invention relates to decreasing the risk of allergic sensitization and its progression to clinical illness whereby allergic diseases such as asthma may be...
April 22, 2015

Vactech announces issuance of EPO patent for Use of Enterovirus for Diagnostics, Treatment and Prevention on Celiac Disease.


This invention relates to diagnostics, and treatment and prevention of Celiac Disease.
November 24, 2014

Enteroviral infections detected in the pancreases of living patients newly diagnosed with Type 1 Diabetes.


Enterovirus infections has been detected in the pancreases of living patients newly diagnosed with Type 1 Diabetes and the research results has...
November 5, 2014

A new vaccine against Coxsackievirus B1 shows good efficacy and reveals no risk for accelerated diabetes development in mouse models.


A preclinical study on the efficacy and safety of an experimental vaccine against Coxsackievirus B1 reveals no risk...
August 8, 2014

Vactech announces issuance of Canadian patent for Prevention of Type 1 Diabetes and other non-Polio Enterovirus Diseases.


This invention relates to the prevention of Type 1 Diabetes and other non-polio enterovirus diseases by a novel vaccination...
September 5, 2013

Risk association between coxsackieviruses and Type 1 Diabetes confirmed in Different European Populations.


The risk association has been confirmed and published in the scientific journal of the American Diabetes Association (Diabetes journal)...
August 23, 2013

Research results indicates risk association between coxsackieviruses and Type 1 Diabetes.


Significant results on the risk association have been published in the scientific journal of the American Diabetes Association (Diabetes journal)...
May 22, 2012

Vactech announces issuance of US patent for Prevention of Allergic Sensitization.


This invention relates to decreasing the risk of allergic sensitization, especially IgE mediated sensitization, and its progression to clinical illness...
July 5, 2011

Vactech announces issuance of a completing US patent for Prevention of Type 1 Diabetes and other non-Polio Enterovirus Diseases.


This invention relates to the prevention of Type 1 Diabetes and other non-polio enterovirus diseases by a novel...
August 15, 2006

Vactech announces issuance of US patent for Prevention of Type 1 Diabetes and other non-Polio Enterovirus Diseases.


This invention relates to the prevention of Type 1 Diabetes and other non-polio enterovirus diseases by a novel vaccination regime...